ArticleOphthalmology science2026
Neurodevelopmental Disorders in Infants Treated with Anti-VEGF Agents versus Laser Photocoagulation or Cryotherapy for Retinopathy of Prematurity.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the incidence of early neurodevelopmental disorders in very preterm infants treated with intravitreal anti-VEGF agents versus laser photocoagulation and/or cryotherapy for retinopathy of prematurity (ROP). Design: Nationwide population-based retrospective cohort study. Participants: All very preterm newborns (gestational age <32 weeks) born in France between 2015 and 2022 who received treatment for ROP with anti-VEGF agents, laser photocoagulation, or cryotherapy within the first 24 weeks of life. Methods: Using the French National Health Data System (Système National des Données de Santé), a medico-administrative database, we compared the incidence of early neurodevelopmental disorders between newborns treated with anti-VEGF agents and those treated with laser photocoagulation and/or cryotherapy, applying a propensity score‑weighted logistic regression model with inverse probability of treatment weighting. Main Outcome Measures: Incidence of early neurodevelopmental disorders within the first 6 years of life. Results: The number of infants treated exclusively with anti-VEGF agents increased by 300% from 2015 to 2022. The primary comparative analysis was conducted on 102 newborns born between 2015 and 2019, for whom mother-infant linkage was available in the Système National des Données de Santé: 59 treated with anti-VEGF agents and 43 with laser and/or cryotherapy. Early neurodevelopmental disorders within the first 6 years of life were not observed more frequently in infants treated with anti-VEGF agents than in those treated with laser and/or cryotherapy (71.4% vs. 58.1%; odds ratio, 1.4; 95% confidence interval, 0.8-2.4; Conclusions: Using intravitreal anti-VEGF agents in very preterm newborns did not increase the risk of early neurodevelopmental disorders within the first 6 years of life. While a small excess risk cannot be formally excluded, these results might be reassuring for clinical practice, particularly given the substantial increase in the use of anti-VEGF agents for the treatment of ROP in recent years. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.